-
Sirnaomics Partners with Hualan Biological to Develop and Commercialize RSV mRNA Vaccine in China
•
Sirnaomics Ltd (HKG: 2257) has entered into a strategic partnership with China’s Hualan Biological Engineering Inc., (SHE: 002007), to enhance the clinical development and commercialization of Sirnaomics’ respiratory syncytial virus (RSV) mRNA vaccine, RV-1770, in China. Under the agreement, Hualan will oversee clinical development, industrialization, and commercialization of the vaccine…
